Hydrocephalus Market Research Report - Global Forecast till 2023

Global Hydrocephalus Research Report: Information by Type (Congenital Hydrocephalus, Acquired Hydrocephalus, Normal-Pressure Hydrocephalus, Ex-Vacuo Hydrocephalus), Diagnostic (CT scan – head, MRI, Head Ultrasound), Treatment (Surgery – Shunt Insertion, Ventriculostomy, Medication), End User (Hospitals & Clinics, Diagnostic Centres, Academic Institutions and Research Organizations) and Region - Forecast till 2023

ID: MRFR/MED/1187-CR | August 2019 | Region: Global | 139 pages

Market Scenario:


The Global Hydrocephalus Market is growing at a healthy pace and is expected to be USD 1,348.00 million in 2017, at a CAGR of 4.4% during the forecast period 2018-2023.


Hydrocephalus is a condition that characterized by buildup of cerebrospinal fluid (CSF) in the brain cavities (ventricles). The ventricles expand as a result of fluid accumulation, causing an abnormal increase in brain size. In normal conditions, the cerebrospinal fluid usually flows through the cavities of the brain and spinal column, but in hydrocephalus, the excessive CSF accumulation causes damage to the brain tissues, leading to a number of brain impairments. This condition can occur in any age, but it is more prevalent in infants and older adults. The increasing prevalence of hydrocephalus is directly responsible for the market growth. The major cause for this condition in children is found to be malnourishment of the fetus. this condition is mostly genetic however, it can also manifest in adults and is known as acquired hydrocephalus.


Shunting is a primary line of treatment for hydrocephalus. Shunting creates a bypass for the accumulated fluid to flow to other parts of the body. The increasing prevalence of traumatic brain injuries due to accidents and shifting patient preference towards minimally invasive surgeries in geriatric population are considered as the key factors that are projected to encourage the growth of the global hydrocephalus market in the coming years. In addition to this, the growing disposable income among consumers and the rapid development in the healthcare infrastructure are further predicted to enhance the growth of the overall market in the next few years.


Market Dynamics


The market for hydrocephalus is not very well developed due to lack of attention paid to the treatment of the disease. Following the development of shunts for draining the accumulated cerebrospinal fluid and scans to diagnose this condition, there have been improvements in terms of treatments to provide short-term relief to patients. However, there are efforts to develop treatments to address the disease at initial stages and this has ensured a positive growth trend for the market.


Further, Posttraumatic hydrocephalus (PTH) is a recurrent and serious complication that follows a traumatic brain injury (TBI). The prevalence of this condition varies greatly based on different criteria for its diagnosis. It can be caused by the blockage of normal cerebrospinal fluid (CSF) flow, overproduction of CSF, or insufficient absorption that result in excessive accumulation of CSF around the brain


The use of ICP devices is for measuring the fluid pressure within the brain which may be caused by trauma or other conditions. ICP monitoring has a significant importance in diagnostic and post-operative procedures with cranial injury as seen in cases of stroke, hydrocephalus, and trauma. According to the estimate of the Centers for Disease Control and Prevention (CDC) in 2017, more than 1.75 million traumatic brain injuries occur in North America, annually and these monitoring devices enable surgeons to save lives of patients with timely intervention and treatment. The increasing accidental cases causing traumatic brain injuries are going to act as drivers for the hydrocephalus market.


Figure 1: - Global Hydrocephalus Share, by Region 2017 (%)
 Hydrocephalus


Sources: WHO, Centers for Medicare & Medicaid Services, Annual Reports, Press Release, White Paper, and Company Presentation


Segmentation


The global Hydrocephalus market is segmented on the basis of type, diagnostic, treatment, end user. On the basis the type, the market is segmented into congenital hydrocephalus, acquired hydrocephalus, normal-pressure hydrocephalus, ex-vacuo hydrocephalus. on the basis of the diagnostic, the market is segmented into CT scan – head, MRI, head ultrasound. on the basis of treatment, it is segmented into surgery – shunt insertion, ventriculostomy, medication. on the basis of end user, it is segmented into hospitals & clinics, diagnostic centres, academic institutions and research organizations


Regional Analysis


The global market for hydrocephalus is segmented on the basis of regions into Americas, Europe, Asia Pacific, and Middle East & Africa.


The Americas held the largest share of the global hydrocephalus market owing to the rising prevalence of hydrocephalus, the presence of a well-developed healthcare sector, and the major market players. The continuous increase in the number of Americans affected from hydrocephalus coupled with ongoing research in neuroscience aid to the market growth. On a regional basis, the Americas is divided into North America and South America. North America is estimated to lead due to the presence of developed economies such as the US and Canada within the region. South America, however, is estimated to have the faster growth.


Europe stands second in the global market due to the constant evaluation of various techniques by neurosurgeons for the improvement of hydrocephalus management, is expected to drive growth in this market. Moreover, shunt manufacturers are engaged in investment for development of novel and improved shunts in order to tackle the pitfalls associated with the existing designs. The child population, aging in between 0 and 14 years, is estimated to increase from 17.6% of the total population in 2013 to 18.4% of the total population by 2020. This provides favorable background for market growth in Europe.


Key Players for the Global Hydrocephalus


Some of the key players in this market are DePuy Synthes, Boston Neurosciences, Medtronic Plc, Integra LifeSciences Corporation, Spiegelberg GmbH & Co. KG, RAUMEDIC Inc, Sophysa SA, Terumo Corporation, Natus Medical Incorporated, Johnson & Johnson Services Inc, B. Braun Melsungen AG, Christoph Miethke GmbH & Co. KG, Tokibo Co., Ltd, HLL Lifecare Limited and others



  • September 2017 Natus Medical Incorporated acquired neurosurgery business assets from Integra LifeSciences, thus entering into the neurosurgery business segment



  • October 2017 Integra Lifesciences acquired Codman Neuro from Johnson & Johnson for USD 1.1 billion. Integra is divesting its assets in order to get FTC's permission on its proposed acquisition of Johnson & Johnson's Codman Neurosurgery business. The Codman Neurosurgery business offers a portfolio of devices focused on hydrocephalus management, neurointensive care, and cranial surgery, and generated net revenues of approximately USD 371.5 million in 2016.


Market Segmentation


Global Hydrocephalus, by Type



  • Congenital hydrocephalus

  • Acquired hydrocephalus

  • Normal-pressure hydrocephalus

  • Ex-vacuo hydrocephalus


Global Hydrocephalus, by Diagnostic



  • CT scan – head

  • MRI

  • Head Ultrasound


Global Hydrocephalus, by Treatment



  • Surgery – Shunt Insertion

  • Ventriculostomy

  • Medication


Global Hydrocephalus, by End User



  • Hospitals & Clinics

  • Diagnostic Centres

  • Academic Institutions and Research Organizations


Intended Audience



  • Pharmaceutical Companies

  • Hospitals

  • Research and Development (R&D) Companies/Laboratories

  • Market Research and Consulting Service Providers

  • Potential Investors



Frequently Asked Questions (FAQ) :


The hydrocephalus market valuation was USD 1348 million in 2017.

The end users are diagnostic centers, hospitals & clinics, academic institutions & research organizations.

The segments are MRI, CT scan – head, and head ultrasound.

America is leading the hydrocephalus market.

Global Hydrocephalus Market - Summary


Overview


Hydrocephalus is medical condition in which excess levels of cerebrospinal fluid (CSF) in the ventricles can increase the intracranial pressure in the brain. This condition in noticeable in infants and older adults. Infants are likely to attain this disorder either due to genetics or malnourishment in the fetal stage.


The global hydrocephalus market is expected to reach a valuation of USD 1,752.07 million by 2023 at a CAGR of 4.4% from 2018 to 2023 (forecast period). The exponential growth is credited to increasing incidence of traumatic brain injuries (TBI). According to the Centers for Disease Control & Prevention (CDC), nearly 1.75 million cases of TBI occurred in 2017. Continuous development of shunts and other equipment for increasing the success of hydrocephalus surgeries is likely to boost market demand.


Favorable medical reimbursement schemes which cover treatment costs can provide the hydrocephalus market the required tailwind. This is backed by inflated healthcare expenditure of nations in the Gulf Cooperation Council (GCC) and others. High prevalence of neurological conditions such as brain aneurysm can further the market growth as well. According to the Brain Aneurysm Foundation, the condition has been responsible for causing 500,000 deaths worldwide annually. Moreover, medical reimbursement schemes covering brain aneurysm treatment such as stents can bode well for the market.


Industry Opportunities


Intraoperative neurophysiological monitoring (IONM) are an array of methods designed to check the functions of nerves during surgery. Emergence of medical institutions which are offering courses to medical professionals for upskilling is likely to bode well for the market. In addition, technological breakthroughs in the form of endovascular embolization and wire micro-guide catheters which can provide a pathway to the brain. Both procedures offer good outcomes with low amount of medical complications.


Segmentation


Types include acquired hydrocephalus, congenital hydrocephalus, ex-vacuo hydrocephalus, and normal-pressure hydrocephalus (NPH). Congenital hydrocephalus dominated the hydrocephalus market in 2017 owing to the condition being prevalent in neonates. It can exhibit a strong growth rate over the forecast period due to efforts by nations to lower the mortality rate caused by the neurological condition. But the NPH segment is expected to exhibit an impressive CAGR owing to its high prevalence in patients above the age of 60.


Methods of diagnosis for the medical condition in the hydrocephalus market include MRI, head ultrasound, and CT scan-head. MRI remains the most trustworthy method and will exhibit the highest CAGR in the market till 2023. The technology can scan accurate images of the brain to discern the presence of malformations. This can be used to detect hydrocephalus and other neurological or neurovascular conditions.


By treatment, the market is segmented into medication, ventriculostomy, and surgery-shunt insertion. The surgery-shunt insertion segment can exhibit an impressive CAGR during the forecast period owing to the improvement shown in draining the excess levels of CSF. Ventriculostomy can display an impressive growth rate owing to extensive application of ventricle shunts used for creating a path for CSF to exit.


End-users in the hydrocephalus market include hospitals & clinics, research institutes & academic centers, and diagnostic centers. Hospitals & clinics can generate significant revenue for the market owing to the institution equipped with intracranial pressure (ICP) monitors. High prevalence of TBI being treated by surgeons at hospitals with high success outcomes can augur well for the segment. But diagnostic centers can display the strongest growth rate owing to the need for high-resolution procedures to detect abnormalities in brain ventricles at an early stage.


Regional Analysis


Geographic segmentation of the hydrocephalus market comprises Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).


The Americas held the highest market share in 2017 owing to high prevalence of neurological conditions, sophisticated healthcare infrastructure, and presence of major players. On the other hand, APAC can display the highest growth rate owing to rapid growth of China and India and their large patient pool. Government support in form of funding to expedite research and development in shunts and other imaging technologies can drive the regional hydrocephalus market till 2023.


Competitive Landscape


Key players in the hydrocephalus market include HLL Lifecare Limited (India), Integra LifeSciences Corporation (U.S.), Johnson & Johnson Services Inc. (U.S.), Natus Medical Incorporated (U.S.), B. Braun Melsungen AG (Germany), Boston Neurosciences (U.S.), Terumo Corporation (U.S.), Medtronic Plc (Ireland), Spiegelberg GmbH & Co. KG (Germany), Sophysa SA (France), RAUMEDIC Inc. (Germany), DePuy Synthes (U.S.), Christoph Miethke GmbH & Co. KG (Germany), and Tokibo Co., Ltd. (Japan).

License

Single User Enterprise User (Buy Premium Reports Chapterwise)
Currency

USD YEN EURO GBP INR
TABLE OF CONTENT

3.1 Scope of Study 20

3.2 Research Objective 20

3.3 List of Assumptions 21

3.4 Market Structure 21

4.1 Research Process 23

4.2 Primary Research 24

4.3 Secondary Research 25

4.4 Market Size Estimation 26

4.5 Forecast Model 26

5.1 Introduction 28

5.2 Drivers 29

5.2.1 Growing Prevalence of Traumatic Brain Injuries 29

5.2.2 Ongoing Product Development & Commercialization Will Boost the Adoption of Hydrocephalus Shunts in the Market 29

5.2.3 Favorable Reimbursement Policies Provide Favorable Background for the Market Growth 29

5.2.4 Increasing Prevalence of Neurovascular Diseases such as Brain Aneurysm, Arteriovenous Malformations (AVMs), and Others, are Likely to Propel the Hydrocephalus Market 30

5.3 Restraints 31

5.3.1 High Procedural Cost of ICP Monitoring Devices 31

5.3.2 Shortage of Trained Professionals 31

5.4 Opportunities 32

5.4.1 Increase in Awareness of Intraoperative Neurophysiological Monitoring (IONM) 32

5.4.2 Increasing Use of Endovascular Embolization for the Treatment of Brain Aneurysm 32

5.4.3 Technological Advancements in Over the Wire Micro Guide Catheters 32

5.5 Challenges 33

5.5.1 Rising Partnership Among Competitors Leading to Rivalry 33

5.6 Changing Economic Conditions Globally 33

6.1 Porter’s Five Forces Model 35

6.1.1 Bargaining Power of Suppliers 35

6.1.2 Bargaining Power of Buyers 36

6.1.3 Threat of New Entrants 36

6.1.4 Threat of Substitutes 36

6.1.5 Intense Rivalry 36

6.2 Value chain analysis 37

6.2.1 R&D 37

6.2.2 Manufacturing 37

6.2.3 Distribution & Sales 37

6.2.4 Post-Sales Monitoring 37

6.3 Investment Opportunities 38

7.1 Introduction 40

7.1.1 Congenital Hydrocephalus 41

7.1.2 Acquired Hydrocephalus 41

7.1.3 Normal-Pressure Hydrocephalus 42

7.1.4 Ex-Vacuo Hydrocephalus 42

8.1 Introduction 44

8.1.1 CT Scan–Head 45

8.1.2 MRI 45

8.1.3 Head Ultrasound 45

9.1 Introduction 47

9.1.1 Surgery–Shunt Insertion 48

9.1.2 Ventriculostomy 48

9.1.3 Medication 48

10.1 Introduction 51

10.1.1 Hospitals & Clinics 52

10.1.2 Diagnostic Centres 52

10.1.3 Academic Institutions and Research Organizations 52

11.1 Introduction 54

11.2 Americas 55

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.2.1 North America 58

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.2.1.1 US 60

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.2.1.2 Canada 62

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.2.2 South America 63

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.3 Europe 66

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.4 Western Europe 69

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.4.1 Germany 71

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.4.2 UK 73

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.4.3 France 75

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.4.4 Spain 76

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.4.5 Italy 78

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.4.6 Rest of Western Europe 80

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.4.7 Eastern Europe 81

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.5 Asia-Pacific 84

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.5.1 China 86

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.5.2 Japan 88

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.5.3 India 90

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.5.4 Australia 91

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.5.5 South Korea 93

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.5.6 Rest of Asia-Pacific 95

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.6 Middle East & Africa 97

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.6.1 Middle East 99

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

11.6.2 Africa 101

Hydrocephalus Market, by Type

Hydrocephalus Market, by Diagnosis

Hydrocephalus Market, by Treatment

Hydrocephalus Market, by End User

12.1 Competitive Scenario 104

12.1.1 Introduction 104

12.2 Company Market Share Analysis 105

12.2.1 Introduction 105

12.3 Key Developments 106

13.1 DePuy Synthes 109

13.1.1 Company Overview 109

13.1.2 Financial Overview 109

13.1.3 Products Offered 110

13.1.4 Key Developments 110

13.1.5 SWOT Analysis 110

13.1.6 Key Strategies 110

13.2 Boston Neurosciences 111

13.2.1 Company Overview 111

13.2.2 Financial Overview 111

13.2.3 Products Offered 111

13.2.4 Key Developments 111

13.2.5 SWOT Analysis 111

13.2.6 Key Strategies 111

13.3 Medtronic Plc 112

13.3.1 Company Overview 112

13.3.2 Financial Overview 112

13.3.3 Products Offered 113

13.3.4 Key Developments 113

13.3.5 SWOT Analysis 113

13.3.6 Key Strategies 114

13.4 Integra LifeSciences Corporation 115

13.4.1 Company Overview 115

13.4.2 Financial Overview 115

13.4.3 Products Offered 116

13.4.4 Key Developments 117

13.4.5 SWOT Analysis 118

13.4.6 Key Strategies 118

13.5 Spiegelberg GmbH & Co. KG 119

13.5.1 Company Overview 119

13.5.2 Financial Overview 119

13.5.3 Products Offered 119

13.5.4 Key Developments 119

13.5.5 SWOT Analysis 119

13.5.6 Key Strategies 120

13.6 RAUMEDIC Inc. 121

13.6.1 Company Overview 121

13.6.2 Financial Overview 121

13.6.3 Products Offered 121

13.6.4 Key Developments 121

13.6.5 SWOT Analysis 121

13.6.6 Key Strategies 121

13.7 Sophysa SA 122

13.7.1 Company Overview 122

13.7.2 Financial Overview 122

13.7.3 Products Offered 122

13.7.4 Key Developments 122

13.7.5 SWOT Analysis 123

13.7.6 Key Strategies 123

13.8 Terumo Corporation 124

13.8.1 Company Overview 124

13.8.2 Financial Overview 124

13.8.3 Products Offered 125

13.8.4 Key Developments 125

13.8.5 SWOT Analysis 125

13.8.6 Key Strategies 125

13.9 Natus Medical Incorporated 126

13.9.1 Company Overview 126

13.9.2 Financial Overview 126

13.9.3 Products Offered 127

13.9.4 Key Developments 127

13.9.5 SWOT Analysis 127

13.9.6 Key Strategies 127

13.10 Johnson & Johnson Services Inc. 128

13.10.1 Company Overview 128

13.10.2 Financial Overview 128

13.10.3 Products Offered 129

13.10.4 Key Developments 129

13.10.5 SWOT Analysis 129

13.10.6 Key Strategies 130

13.11 B. Braun Melsungen AG 131

13.11.1 Company Overview 131

13.11.2 Financial Overview 131

13.11.3 1.10.3 Products Offered 132

13.11.4 Key Developments 132

13.11.5 SWOT Analysis 132

13.11.6 1.10.6 Key Strategies 132

13.12 Christoph Miethke GmbH & Co. KG 133

13.12.1 Company Overview 133

13.12.2 Financial Overview 133

13.12.3 Products Offered 133

13.12.4 Key Developments 133

13.12.5 SWOT Analysis 133

13.12.6 Key Strategies 133

13.13 Tokibo Co., Ltd. 134

13.13.1 Company Overview 134

13.13.2 Financial Overview 134

13.13.3 Products Offered 134

13.13.4 Key Developments 134

13.13.5 SWOT Analysis 134

13.13.6 Key Strategies 134

13.14 HLL Lifecare Limited 135

13.14.1 Company Overview 135

13.14.2 Financial Overview 135

13.14.3 Products Offered 135

13.14.4 Key Developments 135

13.14.5 SWOT Analysis 135

13.14.6 Key Strategies 135

14.1 Discussion Blue Print 137

TABLE 1 MARKET SYNOPSIS 18

TABLE 2 LIST OF ASSUMPTIONS 21

TABLE 3 GLOBAL HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 40

TABLE 4 GLOBAL HYDROCEPHALUS MARKET FOR CONGENITAL HYDROCEPHALUS, BY REGION 2015–2023 (USD MILLION) 41

TABLE 5 GLOBAL HYDROCEPHALUS MARKET FOR ACQUIRED HYDROCEPHALUS, BY REGION 2015–2023 (USD MILLION) 41

TABLE 6 GLOBAL HYDROCEPHALUS MARKET FOR NORMAL-PRESSURE HYDROCEPHALUS, BY REGION 2015–2023 (USD MILLION) 42

TABLE 7 GLOBAL HYDROCEPHALUS MARKET FOR EX-VACUO HYDROCEPHALUS, BY REGION 2015–2023 (USD MILLION) 42

TABLE 8 GLOBAL HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 44

TABLE 9 GLOBAL HYDROCEPHALUS MARKET, FOR CT SCAN–HEAD BY REGION 2015–2023 (USD MILLION) 45

TABLE 10 GLOBAL HYDROCEPHALUS MARKET, FOR MRI BY REGION 2015–2023 (USD MILLION) 45

TABLE 11 GLOBAL HYDROCEPHALUS MARKET FOR HEAD ULTRASOUND, BY REGION 2015–2023 (USD MILLION) 45

TABLE 12 GLOBAL HYDROCEPHALUS MARKET, BY TREATMENT2015–2023 (USD MILLION) 47

TABLE 13 GLOBAL HYDROCEPHALUS MARKET, FOR SURGERY–SHUNT INSERTION BY REGION, 2015–2023 (USD MILLION) 48

TABLE 14 GLOBAL HYDROCEPHALUS MARKET, FOR VENTRICULOSTOMY BY REGION, 2015–2023 (USD MILLION) 48

TABLE 15 GLOBAL HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 48

TABLE 16 GLOBAL HYDROCEPHALUS MARKET, FOR MEDICATION BY REGION, 2015–2023 (USD MILLION) 49

TABLE 17 GLOBAL HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 51

TABLE 18 GLOBAL HYDROCEPHALUS MARKET FOR HOSPITALS & CLINICS, BY REGION 2015–2023 (USD MILLION) 52

TABLE 19 GLOBAL HYDROCEPHALUS MARKET FOR DIAGNOSTIC CENTERS, BY REGION 2015–2023 (USD MILLION) 52

TABLE 20 GLOBAL HYDROCEPHALUS MARKET FOR ACADEMIC INSTITUTIONS AND RESEARCH ORGANIZATIONS, BY REGION 2015–2023 (USD MILLION) 52

TABLE 21 GLOBAL HYDROCEPHALUS MARKET, BY REGION 2015–2023 (USD MILLION) 54

TABLE 22 AMERICAS HYDROCEPHALUS MARKET, BY REGION 2015–2023 (USD MILLION) 55

TABLE 23 AMERICAS HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 56

TABLE 24 AMERICAS HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 56

TABLE 25 AMERICAS HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 56

TABLE 26 AMERICAS HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 57

TABLE 27 AMERICAS HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 57

TABLE 28 NORTH AMERICA HYDROCEPHALUS MARKET, BY COUNTRY 2015–2023 (USD MILLION) 58

TABLE 29 NORTH AMERICA HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 58

TABLE 30 NORTH AMERICA HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 59

TABLE 31 NORTH AMERICA HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 59

TABLE 32 NORTH AMERICA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 59

TABLE 33 NORTH AMERICA HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 60

TABLE 34 US HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 60

TABLE 35 US HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 60

TABLE 36 US HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 61

TABLE 37 US HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 61

TABLE 38 US HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 61

TABLE 39 CANADA HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 62

TABLE 40 CANADA HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 62

TABLE 41 CANADA HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 62

TABLE 42 CANADA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 63

TABLE 43 CANADA HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 63

TABLE 44 SOUTH AMERICA HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 63

TABLE 45 SOUTH AMERICA HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 64

TABLE 46 SOUTH AMERICA HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 64

TABLE 47 SOUTH AMERICA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 64

TABLE 48 SOUTH AMERICA HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 65

TABLE 49 EUROPE HYDROCEPHALUS MARKET, BY REGION 2015–2023 (USD MILLION) 66

TABLE 50 EUROPE HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 66

TABLE 51 EUROPE HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 67

TABLE 52 EUROPE HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 67

TABLE 53 EUROPE HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 67

TABLE 54 EUROPE HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 68

TABLE 55 WESTERN EUROPE HYDROCEPHALUS MARKET, BY COUNTRY 2015–2023 (USD MILLION) 69

TABLE 56 WESTERN EUROPE HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 70

TABLE 57 WESTERN EUROPE HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 70

TABLE 58 WESTERN EUROPE HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 70

TABLE 59 WESTERN EUROPE HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 71

TABLE 60 WESTERN EUROPE HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 71

TABLE 61 GERMANY HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 71

TABLE 62 GERMANY HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 72

TABLE 63 GERMANY HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 72

TABLE 64 GERMANY HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 72

TABLE 65 GERMANY HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 73

TABLE 66 UK HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 73

TABLE 67 UK HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 73

TABLE 68 UK HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 74

TABLE 69 UK HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 74

TABLE 70 UK HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 74

TABLE 71 FRANCE HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 75

TABLE 72 FRANCE HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 75

TABLE 73 FRANCE HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 75

TABLE 74 FRANCE HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 76

TABLE 75 FRANCE HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 76

TABLE 76 SPAIN HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 76

TABLE 77 SPAIN HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 77

TABLE 78 SPAIN HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 77

TABLE 79 SPAIN HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 77

TABLE 80 SPAIN HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 78

TABLE 81 ITALY HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 78

TABLE 82 ITALY HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 78

TABLE 83 ITALY HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 79

TABLE 84 ITALY HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 79

TABLE 85 ITALY HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 79

TABLE 86 . REST OF WESTERN EUROPE HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 80

TABLE 87 REST OF WESTERN EUROPE HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 80

TABLE 88 REST OF WESTERN EUROPE HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 80

TABLE 89 REST OF WESTERN EUROPE HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 81

TABLE 90 REST OF WESTERN EUROPE HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 81

TABLE 91 EASTERN EUROPE HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 81

TABLE 92 EASTERN EUROPE HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 82

TABLE 93 EASTERN EUROPE HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 82

TABLE 94 EASTERN EUROPE HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 82

TABLE 95 EASTERN EUROPE HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 83

TABLE 96 ASIA PACFIC HYDROCEPHALUS MARKET, BY COUNTRY 2015–2023 (USD MILLION) 84

TABLE 97 ASIA-PACIFIC HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 85

TABLE 98 ASIA-PACIFIC HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 85

TABLE 99 ASIA-PACIFIC HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 85

TABLE 100 ASIA-PACIFIC HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 86

TABLE 101 ASIA-PACIFIC HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 86

TABLE 102 CHINA HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 86

TABLE 103 CHINA HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 87

TABLE 104 CHINA HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 87

TABLE 105 CHINA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 87

TABLE 106 CHINA HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 88

TABLE 107 JAPAN HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 88

TABLE 108 JAPAN HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 88

TABLE 109 JAPAN HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 89

TABLE 110 JAPAN HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 89

TABLE 111 JAPAN HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 89

TABLE 112 INDIA HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 90

TABLE 113 INDIA HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 90

TABLE 114 INDIA HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 90

TABLE 115 INDIA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 91

TABLE 116 INDIA HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 91

TABLE 117 AUSTRALIA HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 91

TABLE 118 AUSTRALIA HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 92

TABLE 119 AUSTRALIA HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 92

TABLE 120 AUSTRALIA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 92

TABLE 121 AUSTRALIA HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 93

TABLE 122 SOUTH KOREA HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 93

TABLE 123 SOUTH KOREA HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 93

TABLE 124 SOUTH KOREA HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 94

TABLE 125 SOUTH KOREA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 94

TABLE 126 SOUTH KOREA HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 94

TABLE 127 REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 95

TABLE 128 REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 95

TABLE 129 REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 95

TABLE 130 REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 96

TABLE 131 REST OF ASIA-PACIFIC HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 96

TABLE 132 MIDDLE EAST & AFRICA HYDROCEPHALUS MARKET, BY REGION 2015–2023 (USD MILLION) 97

TABLE 133 MIDDLE EAST & AFRICA MERICAS HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 97

TABLE 134 MIDDLE EAST & AFRICA MERICAS HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 98

TABLE 135 MIDDLE EAST & AFRICA HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 98

TABLE 136 MIDDLE EAST & AFRICA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 98

TABLE 137 MIDDLE EAST & AFRICA HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 99

TABLE 138 MIDDLE EAST HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 99

TABLE 139 MIDDLE EAST HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 99

TABLE 140 MIDDLE EAST HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 100

TABLE 141 MIDDLE EAST HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 100

TABLE 142 MIDDLE EAST HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 100

TABLE 143 AFRICA HYDROCEPHALUS MARKET, BY TYPE 2015–2023 (USD MILLION) 101

TABLE 144 AFRICA HYDROCEPHALUS MARKET, BY DIAGNOSIS 2015–2023 (USD MILLION) 101

TABLE 145 AFRICA HYDROCEPHALUS MARKET, BY TREATMENT 2015–2023 (USD MILLION) 101

TABLE 146 AFRICA HYDROCEPHALUS MARKET, FOR MEDICATION BY TYPE, 2015–2023 (USD MILLION) 102

TABLE 147 AFRICA HYDROCEPHALUS MARKET, BY END USER 2015–2023 (USD MILLION) 102

TABLE 148 GLOBAL HYDROCEPHALUS MARKET: KEY DEVELOPMENT 106

FIGURE 1 GLOBAL HYDROCEPHALUS MARKET: MARKET STRUCTURE 21

FIGURE 2 RESEARCH PROCESS OF MRFR 23

FIGURE 3 TOP-DOWN AND BOTTOM-UP APPROACH 26

FIGURE 4 PORTER’S FIVE FORCES ANALYSIS: GLOBAL HYDROCEPHALUS MARKET 35

FIGURE 5 VALUE CHAIN: GLOBAL HYDROCEPHALUS MARKET 37

FIGURE 6 GLOBAL HYDROCEPHALUS MARKET, BY TYPE 2017 & 2023 (USD MILLION) 41

FIGURE 7 GLOBAL HYDROCEPHALUS MARKET, BY DIAGNOSIS 2017 & 2023 (USD MILLION) 44

FIGURE 8 GLOBAL HYDROCEPHALUS MARKET, BY TREATMENT 2017 & 2023 (USD MILLION) 47

FIGURE 9 GLOBAL HYDROCEPHALUS MARKET, BY END USER 2017 & 2023 (USD MILLION) 51

FIGURE 10 GLOBAL HYDROCEPHALUS MARKET, BY REGION 2017 & 2023 (USD MILLION) 54

FIGURE 11 AMERICAS HYDROCEPHALUS MARKET, BY REGION COUNTRY 2017 (%) 55

FIGURE 12 NORTH AMERICA HYDROCEPHALUS MARKET, BY COUNTRY 2017 (%) 58

FIGURE 13 EUROPE HYDROCEPHALUS MARKET, BY REGION 2017 (%) 66

FIGURE 14 WESTERN EUROPE HYDROCEPHALUS MARKET, BY COUNTRY 2017 (%) 69

FIGURE 15 ASIA-PACIFIC HYDROCEPHALUS MARKET, BY COUNTRY 2017 & 2023 (USD MILLION) 84

FIGURE 16 MIDDLE EAST & AFRICA HYDROCEPHALUS MARKET, BY COUNTRY 2017 (%) 97

FIGURE 17 GLOBAL HYDROCEPHALUS MARKET COMPETITIVE LANDSCAPE (%) 104

FIGURE 18 GLOBAL HYDROCEPHALUS MARKET, MARKET SHARE ANALYSIS 2017 (%) 105

Global Hydrocephalus Market: Competitive Landscape


The prominent players in the global hydrocephalus market are Medtronic Plc (PS Medical), Codman (Johnson & Johnson), Integra LifeSciences Corporation, B. Braun Melsungen AG, DePuy Synthes, Christoph Miethke GmbH & Co. KG, Spiegelberg GmbH & Co. KG and others.


Medtronic Plc (PS Medical) is the holds the largest share for the global hydrocephalus market in 2017. The company is a global healthcare solutions company committed to improving the lives of people through medical technologies, services, and solutions. Medtronic Plc with Covidien has accelerated and advanced its ability to create meaningful innovations for hospitals, health systems, and healthcare providers so that it can deliver the best care possible to patients and their families around the world.


Codman (Johnson & Johnson) holds second position in terms of market share in the global hydrocephalus market in 2017. The company manufactures medical devices for various specialties, such as orthopedics, cardiovascular diseases, and many others. J&J Services has acquired and merged with various other companies to expand its portfolio of endoscopic devices. Ethicon, a subsidiary of J&J offers a broad range of suture needle products


Integra LifeSciences Corporation holds third position in terms of market share in the global hydrocephalus market in 2017. The company is an international leader in medical technology. The key focus of the company is to provide patients with a high level of satisfaction. The company also provides and operates innovative solutions in the field of orthopedic extremity surgery, neurosurgery, and reconstructive and general surgery. In the US, Integra LifeSciences Corporation is one of the leading players for providing surgical devices and instruments to various hospitals, surgery centers, physicians, and dental offices.



  1. Braun Melsungen AG is a leading healthcare supplier. The company provides its products for hospitals, surgeries, private practices (medical care and doctors´ offices), and extracorporeal blood treatments. The company’s product segments include clinical nutrition, urinary care, infection prevention, infusion therapy, diabetes care, neurosurgery, extracorporeal blood treatment, IV drugs, orthopedics, spine, and wound care, among others. The company operates in four major divisions, namely, hospital care, Aesculap, outpatient market, and B. Braun Avitum. With these four divisions, the company has a wide range of products with about 5,000 products, out of which 95% of the products are manufactured by the company. Geographically the company operates in 64 countries in regions such as Europe, Asia-Pacific, Latin America, and the Middle East and Africa.


DePuy Synthes is a contract manufacturing organization of softgel capsules and supplies to the nutritional supplement market. It operates a Good Manufacturing Practices (GMP) facility licensed by the UK Medicines & Healthcare products Regulatory Authority (MHRA). EuroCaps is a part of DCC Health and Beauty Solutions, a subsidiary of DCC Healthcare.


Medtronic Plc (PS Medical), and Codman (Johnson & Johnson) are the major companies for hydrocephalus operating on a global scale. The lower market share of Spiegelberg GmbH & Co. KG can be attributed to fewer products offering, as compared to other major players. Key players such as Christoph Miethke GmbH & Co. KG, RAUMEDIC Inc., Natus Medical Incorporated, Terumo Corporation, Boston Neurosciences increase the level of competition in the global hydrocephalus market, as these companies are expected to expand their product portfolios, with the help of other business units, to increase their market share.